Pharmacoepidemiology of Diabetes

  • Jørgen Rungby
  • Andrew J. Krentz

Keywords: Pharmacoepidemiology, Pharmacoeconomics, Pharmacosurveillance.


Human Insulin Antidiabetic Drug Insulin Analogue International Diabetes Federation Antidiabetic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    WHO Expert Committee on Diabetes Mellitus. Second Report. Technical Report Series 646. Geneva: WHO, 1980.Google Scholar
  2. 2.
    World Health Organization Study Group. Diabetes Mellitus. WHO Technical Report Series 727. Geneva: WHO, 1985.Google Scholar
  3. 3.
    World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999.Google Scholar
  4. 4.
    World Health Organization. Definition and diagnosis of diabetes mellitus an intermediate hyperglycaemia. Report of a WHO/IDF Consultation. Geneva: WHO, 2006.Google Scholar
  5. 5.
    The Expert Committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183–1197.Google Scholar
  6. 6.
    The Expert Committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160–3167.Google Scholar
  7. 7.
    Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059–1062.CrossRefPubMedGoogle Scholar
  8. 8.
    Rusforth NB, Bennett PH, Steinberg AG, nBurch TA, Miller M. Diabetes in the Pima Indians: evidence of bimodality in glucose tolerance distributions. Diabetes 1971;20:756–65.Google Scholar
  9. 9.
    Lim T-O, Bakri R, Morad Z, Hamid MA. Bimodality in blood glucose distribution. Is it universal? Diabetes Care 2002;25:2212–2217.CrossRefPubMedGoogle Scholar
  10. 10.
    Borch-Johnsen K, Colagiuri S, Vistisen D on behalf of the DETECT-2 collaboration. Is there a bimodal distribution of plasma glucose. American Diabetes Association Annual Scientific Meeting, 2006, Diabetes 2006;55(Suppl. 1):A19, Abstract 77.Google Scholar
  11. 11.
    The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine 2001;161:397–405.CrossRefGoogle Scholar
  12. 12.
    DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change the phenotype of patients with diabetes? British Medical Journal 1998;317:371–375.Google Scholar
  13. 13.
    DECODE-Study Group. Glucose tolerance and mortality. Comparison of the WHO and ADA diagnostic criteria. Lancet 1999;354(9179):617–621.Google Scholar
  14. 14.
    Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–2012.CrossRefPubMedGoogle Scholar
  15. 15.
    Kuzuya T, Matsuda A. Classification of diabetes on the basis of etiologies versus the degree of insulin deficiency. Diabetes Care 1997;20:219–220.PubMedGoogle Scholar
  16. 16.
    Bosi EP, Garancini MP, Poggiali F, Bonifacio E, Gallus G: Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet auto antibodies in the general adult population of northern Italy. Diabetologia 1999;42:840–844.CrossRefPubMedGoogle Scholar
  17. 17.
    Ruige JB, Batstra MR, Aanstoot HJ, Bouter LM, Bruining GJ, De Neeling JN, Heine RJ: Low prevalence of antibodies to GAD65 in a 50- to 74-year-old general Dutch population. The Hoorn Study. Diabetes Care, 1997;20:1108–1110.CrossRefPubMedGoogle Scholar
  18. 18.
    DECODE Study Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999;42:647–654.CrossRefGoogle Scholar
  19. 19.
    Pan X, Li G, Hu Y-H, Wang J, Yang W, An Z et al. Effects of diet and exercise in preventing NIDDM in people with Impaired Glukose Tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.CrossRefPubMedGoogle Scholar
  20. 20.
    Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New English Journal of Medicine 2001;344:1343–1350.CrossRefGoogle Scholar
  21. 21.
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. New English Journal of Medicine 2002;346;393–403.CrossRefGoogle Scholar
  22. 22.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072–2077.CrossRefPubMedGoogle Scholar
  23. 23.
    Glümer C, Vistisen D, Borch-Johnsen K, Colagiuri S; DETECT-2 Collaboration. Risk scores for type 2 diabetes can be applied in some populations but not all. Diabetes Care 2006(Feb);29(2):410–414.CrossRefPubMedGoogle Scholar
  24. 24.
    Borch-Johnsen K, Colagiuri S, Balkau B, Glümer C, Carstensen B, Ramachandran A, Dong Y, Gao W. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia 2004;47:1396–1402.CrossRefPubMedGoogle Scholar
  25. 25.
    Glümer C, Jørgensen T, Borch-Johnsen K. Prevalence of diabetes and impaired glucose regulation in a Danish population – The Inter99 study. Diabetes Care 2003;26(8):2335–2340.CrossRefPubMedGoogle Scholar
  26. 26.
    Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). British Medical Journal 2001;322:15–18.CrossRefPubMedGoogle Scholar
  27. 27.
    Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R, Thienpont L, Umemoto M, Weykamp C. Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical Chemistry and Laboratory Medicine, 2002;40:78–89.CrossRefPubMedGoogle Scholar
  28. 28.
    Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated haemoglobin: Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA, 1999;281:1203–1210.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jørgen Rungby
    • 1
  • Andrew J. Krentz
    • 1
  1. 1.Department of EndocrinologyAarhus University HospitalDenmark

Personalised recommendations